ROC curves confirmed that NLR, ATIII and FVIII were moderately accurate biomarkers for glioma compared to both MS patients and healthy controls whereas d-dimer was a moderately accurate marker once compared to controls but not to MS patients (Table 3(Tab. This evidence concerns the gene SERPINC1 and central nervous system cancer.